Michele Tameris

Summary

Affiliation: University of Cape Town
Country: South Africa

Publications

  1. ncbi request reprint Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
    Michele D Tameris
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Lancet 381:1021-8. 2013
  2. pmc Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG
    Michele Tameris
    South African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine IIDMM and School of Child and Adolescent Health, University of Cape Town, Brewelskloof Hospital, Haarlem Street, Worcester, Western Cape 6850, South Africa
    Tuberculosis (Edinb) 93:143-9. 2013
  3. doi request reprint Screening for TB in high school adolescents in a high burden setting in South Africa
    Hassan Mahomed
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Tuberculosis (Edinb) 93:357-62. 2013
  4. pmc Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function
    One B Dintwe
    South African Tuberculosis Vaccine Initiative and School of Child and Adolescent Health, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Eur J Immunol 43:2409-20. 2013
  5. doi request reprint Phenotypic variability in childhood TB: implications for diagnostic endpoints in tuberculosis vaccine trials
    Humphrey Mulenga
    South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town, South Africa
    Vaccine 29:4316-21. 2011
  6. pmc Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Observatory, South Africa
    Eur J Immunol 40:279-90. 2010
  7. doi request reprint Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, South Africa
    J Infect Dis 203:1832-43. 2011
  8. pmc HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guérin vaccine
    Nazma Mansoor
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    J Infect Dis 199:982-90. 2009
  9. pmc A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 185:769-78. 2012
  10. pmc Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults
    Cheryl L Day
    South African Tuberculosis Vaccine Initiative and School of Child and Adolescent Health, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa
    Am J Respir Crit Care Med 188:492-502. 2013

Collaborators

Detail Information

Publications20

  1. ncbi request reprint Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
    Michele D Tameris
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Lancet 381:1021-8. 2013
    ..We aimed to assess safety, immunogenicity, and efficacy of MVA85A against tuberculosis and Mycobacterium tuberculosis infection in infants...
  2. pmc Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG
    Michele Tameris
    South African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine IIDMM and School of Child and Adolescent Health, University of Cape Town, Brewelskloof Hospital, Haarlem Street, Worcester, Western Cape 6850, South Africa
    Tuberculosis (Edinb) 93:143-9. 2013
    ..A phase IIb trial of a candidate vaccine, MVA85A, was conducted in a high burden setting in South Africa to evaluate proof-of-concept efficacy for prevention of TB in infants...
  3. doi request reprint Screening for TB in high school adolescents in a high burden setting in South Africa
    Hassan Mahomed
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Tuberculosis (Edinb) 93:357-62. 2013
    ..The screening tools evaluated in this study may not be practical for routine use owing to low positive predictive values but may be useful in TB vaccine clinical trials...
  4. pmc Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function
    One B Dintwe
    South African Tuberculosis Vaccine Initiative and School of Child and Adolescent Health, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Eur J Immunol 43:2409-20. 2013
    ..Importantly, surface phenotypes commonly used as proxies for memory T-cell function did not associate with functional effects of vaccination. ..
  5. doi request reprint Phenotypic variability in childhood TB: implications for diagnostic endpoints in tuberculosis vaccine trials
    Humphrey Mulenga
    South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town, South Africa
    Vaccine 29:4316-21. 2011
    ....
  6. pmc Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Observatory, South Africa
    Eur J Immunol 40:279-90. 2010
    ..This includes induction of novel Th1-cell populations that have not been previously described in humans...
  7. doi request reprint Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, South Africa
    J Infect Dis 203:1832-43. 2011
    ..We assessed the safety of and characterized the T cell response induced by 3 doses of the candidate vaccine, MVA85A, in BCG-vaccinated infants from a setting where tuberculosis is endemic...
  8. pmc HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guérin vaccine
    Nazma Mansoor
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    J Infect Dis 199:982-90. 2009
    ..Information regarding the immunogenicity of BCG is imperative for the risk/benefit assessment of BCG vaccination in HIV-infected infants; however, no such data exist...
  9. pmc A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 185:769-78. 2012
    ..Novel tuberculosis (TB) vaccines should be safe and effective in populations infected with Mycobacterium tuberculosis (M.tb) and/or HIV for effective TB control...
  10. pmc Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults
    Cheryl L Day
    South African Tuberculosis Vaccine Initiative and School of Child and Adolescent Health, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa
    Am J Respir Crit Care Med 188:492-502. 2013
    ..Tuberculosis (TB) is a major cause of morbidity and mortality worldwide, thus there is an urgent need for novel TB vaccines...
  11. doi request reprint Diagnostic features associated with culture of Mycobacterium tuberculosis among young children in a vaccine trial setting
    Kany Kany A Luabeya
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Pediatr Infect Dis J 31:42-6. 2012
    ..To identify diagnostic features associated with culture of Mycobacterium tuberculosis (MTB), the standard for tuberculosis (TB) diagnosis, to inform clinical end point definitions for new TB vaccine trials...
  12. ncbi request reprint SATVI - after 10 years closing in on a new and better vaccine to prevent tuberculosis
    Willem A Hanekom
    South African TB Vaccine Initiative, Faculty of Health Sciences, University of Cape Town
    S Afr Med J 102:438-41. 2012
    ..SATVI is now widely regarded as the leading TB vaccine clinical research site in the world...
  13. pmc The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults
    Brian Abel
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, UCT Health Sciences, Anzio Road, Observatory 7925, Cape Town, South Africa
    Am J Respir Crit Care Med 181:1407-17. 2010
    ..AERAS-402 is a novel tuberculosis vaccine designed to boost immunity primed by bacillus Calmette-Guérin (BCG), the only licensed vaccine...
  14. pmc Isolation of non-tuberculous mycobacteria in children investigated for pulmonary tuberculosis
    Mark Hatherill
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa
    PLoS ONE 1:e21. 2006
    ..To evaluate the frequency and clinical significance of non-tuberculous mycobacteria (NTM) isolates among children investigated for pulmonary tuberculosis in a rural South African community...
  15. pmc Structured approaches for the screening and diagnosis of childhood tuberculosis in a high prevalence region of South Africa
    Mark Hatherill
    School of Child and Adolescent Health, University of Cape Town, Anzio Road, Cape Town, 7925, South Africa
    Bull World Health Organ 88:312-20. 2010
    ....
  16. pmc TB incidence in an adolescent cohort in South Africa
    Hassan Mahomed
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Cape Town, South Africa
    PLoS ONE 8:e59652. 2013
    ..We conducted a study to determine the TB incidence rates and risk factors for TB disease in a cohort of school-going adolescents in a high TB burden area in South Africa...
  17. doi request reprint The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
    Michele Tameris
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    PLoS ONE 9:e87340. 2014
    ..We determined if a MVA85A viral-vector boost could enhance the durability of mycobacteria-specific T cell responses above those induced by BCG alone...
  18. pmc Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa
    Tony Hawkridge
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Observatory, South Africa
    J Infect Dis 198:544-52. 2008
    ..We investigated the safety and immunogenicity of MVA85A in mycobacteria-exposed--but Mycobacterium tuberculosis-uninfected--healthy adults from a region of South Africa where TB is endemic...
  19. pmc Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial
    Anthony Hawkridge
    South African Tuberculosis Vaccine Initiative, University of Cape Town, South Africa
    BMJ 337:a2052. 2008
    ..To compare the incidence of tuberculosis over two years in infants vaccinated at birth with intradermal BCG or with percutaneous BCG...
  20. pmc Significantly skewed memory CD8+ T cell subsets in HIV-1 infected infants during the first year of life
    Nazma Mansoor
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Anzio Road, Observatory, 7925, South Africa
    Clin Immunol 130:280-9. 2009
    ..We concluded that the proportion of naive, memory, effector and senescent CD8(+) T cells during the first year of life is significantly altered by HIV-1 infection...